Braveheart Bio Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

Div Yld LY

—

Div Yld TTM

—

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Key people

Travis Murdoch

President, Chief Executive Officer · since 2024

Paul Rickey

Chief Financial Officer · since 2024

Marc Evanchik

Senior Vice President - Pharmacology and Translational Medicine · since 2024

Natalie Dement

Vice President, Head - Legal · since 2024

Amy Feng

Vice President - Biometrics and Data Management · since 2024

URL

https://www.braveheart.bio

IPO date

Aug 06, 2026

Employees

Domiciled in

Incorporated in

Valuation

No data to show